chlorine has been researched along with Deep Vein Thrombosis in 33 studies
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to develop and validate a new fibrin-targeted imaging agent that enables high-resolution near-infrared fluorescence (NIRF) imaging of deep vein thrombosis (DVT)." | 7.78 | Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence. ( Bhayana, B; Hara, T; Jaffer, FA; Kessinger, CW; Khatri, A; Lin, CP; McCarthy, JR; Tearney, GJ; Thompson, B; Weissleder, R, 2012) |
| "Human obesity is associated with an increased risk for arterial and venous thrombosis and with elevated levels of leptin in the blood." | 7.72 | Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. ( Dellas, C; Konstantinides, S; Loskutoff, DJ; Neels, JG; Schäfer, K, 2004) |
| "AEW significantly reduced thrombus weight." | 5.62 | Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation. ( Gui, S; Li, P; Lin, B; Tang, P; Wu, Z; Yang, W; Ye, Y; Zhan, Y, 2021) |
| "Deep vein thrombosis was induced by exposure to ferric chloride or ligation of the infrarenal vena cava of C57BL/6 mice after pretreatment with enoxaparin, ticagrelor or vehicle and in P2Y(12-/-) mice." | 3.79 | Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition. ( Bode, C; Boeynaems, JM; Duerschmied, D; Guenther, F; Hein, L; Herr, N; Idzko, M; Mauler, M; Robaye, B; Roming, F; Von Zur Muhlen, C; Witsch, T, 2013) |
| "The goal of this study was to develop and validate a new fibrin-targeted imaging agent that enables high-resolution near-infrared fluorescence (NIRF) imaging of deep vein thrombosis (DVT)." | 3.78 | Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence. ( Bhayana, B; Hara, T; Jaffer, FA; Kessinger, CW; Khatri, A; Lin, CP; McCarthy, JR; Tearney, GJ; Thompson, B; Weissleder, R, 2012) |
| "Murine (C57BL/6 mice) models of ferric chloride (FeCl(3))-induced carotid arterial and vena cava thrombosis were established." | 3.74 | Lipopolysaccharide augments venous and arterial thrombosis in the mouse. ( Wang, X, 2008) |
| "To further explore the relationship between FXI and venous thrombosis, we evaluated FXI-deficient and wild-type mice in a ferric chloride (FeCl(3))-induced vena cava thrombosis model." | 3.73 | Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. ( Gailani, D; Hsu, MY; Ogletree, ML; Schumacher, WA; Seiffert, DA; Smith, PL; Wang, X, 2006) |
| "Human obesity is associated with an increased risk for arterial and venous thrombosis and with elevated levels of leptin in the blood." | 3.72 | Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. ( Dellas, C; Konstantinides, S; Loskutoff, DJ; Neels, JG; Schäfer, K, 2004) |
| " In three different types of thrombosis models in rats, including stasis and thrombin-induced venous, glass surface-activated arterio-venous shunt, and ferric chloride-induced arterial thrombosis models, CX-397 and rHV-1 elicited potent antithrombotic effects, where the minimum effective doses of rHV-1 tended to be higher than those of CX-397 in the arterio-venous shunt and arterial thrombosis models." | 3.70 | Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. ( Fukazawa, T; Goto, Y; Hayashi, H; Inoue, Y; Komatsu, Y, 1999) |
| "It can lead to pulmonary embolism with severe respiratory insufficiency and risk of death." | 2.66 | By word of mouse: using animal models in venous thrombosis research. ( Brill, A; Campos, J, 2020) |
| "Mouse models of venous thrombosis contribute to our understanding of the initiation, propagation, and resolution of venous thrombus, as well as allow for the evaluation of new pharmaceutical approaches to prophylaxis and treatment of deep vein thrombosis." | 2.48 | Critical review of mouse models of venous thrombosis. ( Diaz, JA; Henke, PK; Mackman, N; Myers, DD; Obi, AT; Wakefield, TW; Wrobleski, SK, 2012) |
| "AEW significantly reduced thrombus weight." | 1.62 | Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation. ( Gui, S; Li, P; Lin, B; Tang, P; Wu, Z; Yang, W; Ye, Y; Zhan, Y, 2021) |
| "Leading experts in venous thrombosis research came together through the American Venous Forum to develop a consensus on maximizing the utility and application of available mouse models of venous thrombosis." | 1.51 | Choosing a Mouse Model of Venous Thrombosis. ( Cooley, B; Diaz, JA; Grover, SP; Henke, PK; Lal, BK; Mackman, N; Palmer, OR; Saha, P; Smith, A; Wakefield, TW, 2019) |
| "In addition, a mouse venous thrombosis model was constructed and treated with miR-126-Exo to clarify the therapeutic effect of miR-126-Exo by histological analysis." | 1.48 | Endothelial progenitor cell-derived exosomes, loaded with miR-126, promoted deep vein thrombosis resolution and recanalization. ( Liu, X; Lu, D; Ma, T; Meng, Q; Shen, Z; Sun, J; Yang, J; Yang, Z; Zhang, J; Zhang, Z, 2018) |
| "Fibrin deposition was significantly greater in VGs of CRP-Tg mice than in WT controls." | 1.40 | C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts. ( Fay, WP; Fish, PM; Ji, Y; Lohman, AW; Strawn, TL; Szalai, AJ; Wu, J, 2014) |
| "Venous thrombosis was induced by electrolytic stimulus to the femoral vein or inferior vena cava ligation." | 1.39 | Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. ( Aleman, MM; Byrnes, JR; Cooley, BC; Heisler, MJ; Machlus, KR; Walton, BL; Wang, JG; Wolberg, AS, 2013) |
| "Animal models studying venous thrombosis are scarce and, in most cases, very crude and rely on sacrificing the animals to excise formed thrombi." | 1.38 | In vivo monitoring of venous thrombosis in mice. ( Aghourian, MN; Blostein, MD; Lemarié, CA, 2012) |
| "Venous thrombosis is augmented by overexpression of the cellular senescence protein p16(INK4a)." | 1.37 | Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. ( Cardenas, JC; Church, FC; Krishnamurthy, J; Owens, AP; Sharpless, NE; Whinna, HC, 2011) |
| "Protein infusion of FIX-Triple into haemophilia B mice was not thrombogenic, even at a dose of 13-fold higher than FIX-WT." | 1.36 | FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. ( Kao, CY; Kao, JT; Lin, CN; Lin, SW; Shi, GY; Tao, MH; Wu, HL; Yang, YL; Yu, IS, 2010) |
| "Dalteparin was used as a reference compound." | 1.36 | Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010) |
| "This study compared arterial to venous thrombosis in the mutationally analogous Factor V Leiden mouse." | 1.34 | Increased venous versus arterial thrombosis in the Factor V Leiden mouse. ( Chen, CY; Cooley, BC; Schmeling, G, 2007) |
| "Vena cava thrombosis was induced by either oxidative injury to topical FeCl(2) (FeCl(2)-VT) or stenosis-limited blood flow and a hypotonic pressure stress (stasis-VT) in rats." | 1.34 | Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction. ( Hsu, MY; Monticello, TM; Schumacher, WA; Steinbacher, TE; Wang, X, 2007) |
| " Dose-response studies identified a PCI dose (5 mg kg(-1) bolus plus 5 mg kg(-1) h(-1), i." | 1.33 | Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. ( Hsu, MY; Ogletree, ML; Schumacher, WA; Smith, PL; Wang, X, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 20 (60.61) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Campos, J | 1 |
| Brill, A | 1 |
| Li, P | 1 |
| Lin, B | 2 |
| Tang, P | 1 |
| Ye, Y | 1 |
| Wu, Z | 1 |
| Gui, S | 1 |
| Zhan, Y | 1 |
| Yang, W | 1 |
| Song, W | 1 |
| Ci, H | 1 |
| Tian, G | 1 |
| Zhang, Y | 1 |
| Ge, X | 1 |
| Sun, J | 1 |
| Zhang, Z | 2 |
| Ma, T | 1 |
| Yang, Z | 1 |
| Zhang, J | 1 |
| Liu, X | 1 |
| Lu, D | 1 |
| Shen, Z | 1 |
| Yang, J | 1 |
| Meng, Q | 1 |
| Diaz, JA | 2 |
| Saha, P | 1 |
| Cooley, B | 1 |
| Palmer, OR | 1 |
| Grover, SP | 1 |
| Mackman, N | 2 |
| Wakefield, TW | 2 |
| Henke, PK | 3 |
| Smith, A | 1 |
| Lal, BK | 1 |
| Guenther, F | 1 |
| Herr, N | 1 |
| Mauler, M | 1 |
| Witsch, T | 1 |
| Roming, F | 1 |
| Hein, L | 1 |
| Boeynaems, JM | 1 |
| Robaye, B | 1 |
| Idzko, M | 1 |
| Bode, C | 1 |
| Von Zur Muhlen, C | 1 |
| Duerschmied, D | 1 |
| Aleman, MM | 1 |
| Walton, BL | 1 |
| Byrnes, JR | 1 |
| Wang, JG | 1 |
| Heisler, MJ | 1 |
| Machlus, KR | 1 |
| Cooley, BC | 3 |
| Wolberg, AS | 1 |
| Zhou, W | 1 |
| Abdurahman, A | 1 |
| Umar, A | 1 |
| Iskander, G | 1 |
| Abdusalam, E | 1 |
| Berké, B | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Ji, Y | 1 |
| Fish, PM | 1 |
| Strawn, TL | 1 |
| Lohman, AW | 1 |
| Wu, J | 1 |
| Szalai, AJ | 1 |
| Fay, WP | 1 |
| Cui, G | 1 |
| Shan, L | 1 |
| Guo, L | 1 |
| Chu, IK | 1 |
| Li, G | 1 |
| Quan, Q | 1 |
| Zhao, Y | 1 |
| Chong, CM | 1 |
| Yu, P | 1 |
| Hoi, MP | 1 |
| Sun, Y | 1 |
| Wang, Y | 1 |
| Lee, SM | 1 |
| Xie, H | 1 |
| Kong, X | 1 |
| Zhou, H | 1 |
| Xie, Y | 1 |
| Sheng, L | 1 |
| Wang, T | 1 |
| Xia, L | 1 |
| Yan, J | 1 |
| Kao, CY | 1 |
| Lin, CN | 1 |
| Yu, IS | 1 |
| Tao, MH | 1 |
| Wu, HL | 1 |
| Shi, GY | 1 |
| Yang, YL | 1 |
| Kao, JT | 1 |
| Lin, SW | 1 |
| Pehrsson, S | 1 |
| Johansson, K | 1 |
| Kjaer, M | 1 |
| Elg, M | 1 |
| Cardenas, JC | 1 |
| Owens, AP | 1 |
| Krishnamurthy, J | 1 |
| Sharpless, NE | 1 |
| Whinna, HC | 1 |
| Church, FC | 1 |
| Aghourian, MN | 1 |
| Lemarié, CA | 1 |
| Blostein, MD | 1 |
| Obi, AT | 1 |
| Myers, DD | 1 |
| Wrobleski, SK | 1 |
| Bird, JE | 2 |
| Smith, PL | 5 |
| Wang, X | 7 |
| Schumacher, WA | 6 |
| Barbera, F | 2 |
| Revelli, JP | 1 |
| Seiffert, D | 1 |
| Huang, C | 1 |
| Hara, T | 1 |
| Bhayana, B | 1 |
| Thompson, B | 1 |
| Kessinger, CW | 2 |
| Khatri, A | 1 |
| McCarthy, JR | 2 |
| Weissleder, R | 2 |
| Lin, CP | 2 |
| Tearney, GJ | 1 |
| Jaffer, FA | 2 |
| Joglekar, MV | 1 |
| Ware, J | 1 |
| Xu, J | 1 |
| Fitzgerald, ME | 1 |
| Gartner, TK | 1 |
| Crescente, M | 1 |
| Thomas, GM | 1 |
| Demers, M | 1 |
| Voorhees, JR | 1 |
| Wong, SL | 1 |
| Ho-Tin-Noé, B | 1 |
| Wagner, DD | 1 |
| Ripplinger, CM | 1 |
| Li, C | 1 |
| Kim, JW | 1 |
| Konstantinides, S | 1 |
| Schäfer, K | 1 |
| Neels, JG | 1 |
| Dellas, C | 1 |
| Loskutoff, DJ | 1 |
| Röttger, C | 1 |
| Madlener, K | 1 |
| Heil, M | 1 |
| Gerriets, T | 1 |
| Walberer, M | 1 |
| Wessels, T | 1 |
| Bachmann, G | 1 |
| Kaps, M | 1 |
| Stolz, E | 1 |
| Peternel, L | 1 |
| Drevensek, G | 1 |
| Cerne, M | 1 |
| Stalc, A | 1 |
| Stegnar, M | 1 |
| Budihna, MV | 1 |
| Szema, L | 1 |
| Chen, CY | 2 |
| Schwab, JP | 1 |
| Schmeling, G | 2 |
| Hsu, MY | 4 |
| Ogletree, ML | 2 |
| Steinbacher, TE | 1 |
| Monticello, TM | 1 |
| Gailani, D | 1 |
| Seiffert, DA | 1 |
| Tamasi, JA | 1 |
| Bird, E | 1 |
| Komatsu, Y | 1 |
| Inoue, Y | 1 |
| Goto, Y | 1 |
| Fukazawa, T | 1 |
| Hayashi, H | 1 |
2 reviews available for chlorine and Deep Vein Thrombosis
| Article | Year |
|---|---|
By word of mouse: using animal models in venous thrombosis research.
Topics: Animals; Chlorides; Constriction, Pathologic; Disease Models, Animal; Femoral Vein; Ferric Compounds | 2020 |
Critical review of mouse models of venous thrombosis.
Topics: Animals; Chlorides; Constriction; Disease Models, Animal; Electrolysis; Ferric Compounds; Ligation; | 2012 |
31 other studies available for chlorine and Deep Vein Thrombosis
| Article | Year |
|---|---|
Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation.
Topics: Animals; Antioxidants; Chlorides; Ferric Compounds; Leeches; NF-E2-Related Factor 2; Oxidative Stres | 2021 |
Edoxaban improves venous thrombosis via increasing hydrogen sulfide and homocysteine in rat model.
Topics: Animals; Anticoagulants; Chlorides; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Disease | 2017 |
Endothelial progenitor cell-derived exosomes, loaded with miR-126, promoted deep vein thrombosis resolution and recanalization.
Topics: Animals; Base Sequence; Bone Marrow Cells; Cadherins; Cell Movement; Cellular Senescence; Chlorides; | 2018 |
Choosing a Mouse Model of Venous Thrombosis.
Topics: Algorithms; Animals; Chlorides; Disease Models, Animal; Electrolysis; Endothelial Cells; Endothelium | 2019 |
Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition.
Topics: Adenosine; Animals; Anticoagulants; Chlorides; Contrast Media; Enoxaparin; Ferric Compounds; Male; M | 2013 |
Elevated prothrombin promotes venous, but not arterial, thrombosis in mice.
Topics: Animals; Blood Coagulation; Blood Platelets; Carotid Arteries; Chlorides; Disease Models, Animal; Fe | 2013 |
Effects of Cydonia oblonga Miller extracts on blood hemostasis, coagulation and fibrinolysis in mice, and experimental thrombosis in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood Coagulation; Cardiovascular Agents; Carotid Artery Thro | 2014 |
C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts.
Topics: Animals; C-Reactive Protein; Cell Movement; Chlorides; Coronary Artery Bypass; Ferric Compounds; Fib | 2014 |
Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Cell Adhesion Molecules; Chlorides; Disease Models, | 2015 |
TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Carotid Art | 2015 |
FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
Topics: Animals; Chlorides; Coagulants; Dependovirus; Disease Models, Animal; Dose-Response Relationship, Dr | 2010 |
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep | 2010 |
Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Bone Marrow Transplantation; Chlorides; Cyclin- | 2011 |
In vivo monitoring of venous thrombosis in mice.
Topics: Animals; Anticoagulants; Blood Coagulation; Chlorides; Dalteparin; Disease Models, Animal; Ferric Co | 2012 |
Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait.
Topics: Animals; Bleeding Time; Chlorides; Disease Models, Animal; Ferric Compounds; Hemorrhage; Hemostasis; | 2012 |
A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis.
Topics: Animals; Blood Platelets; Chlorides; Deoxyadenine Nucleotides; Ferric Compounds; Gene Deletion; Mice | 2012 |
Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence.
Topics: Animals; Chlorides; Disease Models, Animal; Femoral Vein; Ferric Compounds; Fibrin; Fluorescent Dyes | 2012 |
Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice.
Topics: Animals; Blood Platelets; Chlorides; Disease Models, Animal; Ferric Compounds; Mice; Platelet Glycop | 2013 |
ADAMTS13 exerts a thrombolytic effect in microcirculation.
Topics: ADAM Proteins; ADAMTS13 Protein; Animals; Chlorides; Computer Systems; Disease Models, Animal; Drug | 2012 |
Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging.
Topics: Animals; Biomarkers; Chlorides; Dextrans; Disease Models, Animal; Femoral Vein; Ferric Compounds; Fl | 2012 |
Inhibition of endogenous leptin protects mice from arterial and venous thrombosis.
Topics: Animals; Antibodies, Blocking; Arterial Occlusive Diseases; Chlorides; Ferric Compounds; Leptin; Mic | 2004 |
Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis.
Topics: Abciximab; Angiography; Animals; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Chlorides; | 2005 |
Evaluation of two experimental venous thrombosis models in the rat.
Topics: Animals; Blood Coagulation Tests; Chlorides; Disease Models, Animal; Female; Ferric Compounds; Hemos | 2005 |
A murine model of deep vein thrombosis: characterization and validation in transgenic mice.
Topics: Animals; Anticoagulants; Chlorides; Coronary Artery Disease; Coronary Vessels; Disease Models, Anima | 2005 |
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Topics: Animals; Carboxypeptidase B2; Carboxypeptidases; Carotid Artery Thrombosis; Chlorides; Disease Model | 2006 |
Increased venous versus arterial thrombosis in the Factor V Leiden mouse.
Topics: Amino Acid Substitution; Animals; Arginine; Arterial Occlusive Diseases; Arteries; Chlorides; Diseas | 2007 |
Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction.
Topics: Animals; Blood Platelets; Chemokine CCL2; Chlorides; Disease Models, Animal; Ferric Compounds; Gene | 2007 |
Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.
Topics: Animals; Chlorides; Disease Models, Animal; Factor XI Deficiency; Ferric Compounds; Fibrinolysis; Fi | 2006 |
Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Topics: Animals; Bleeding Time; Carboxypeptidase B2; Carotid Artery Diseases; Chlorides; Coagulants; Disease | 2007 |
Lipopolysaccharide augments venous and arterial thrombosis in the mouse.
Topics: Animals; Arteries; Carotid Artery Thrombosis; Chlorides; Disease Models, Animal; Dose-Response Relat | 2008 |
Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Topics: Amino Acid Sequence; Animals; Arginine; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; | 1999 |